Regulatory shifts and next‑gen therapies transform rare disease R&D

This cluster tracks a broad push to accelerate treatments for rare and ultra‑rare conditions, from the FDA’s new plausible‑mechanism and individualized therapy frameworks to fresh Breakthrough Therapy designations like nomlabofusp for Friedreich ataxia. Coverage spans efforts to revive stalled cell and gene therapies, rethink trial design in rare neurodegeneration, and refine clinical care for disorders such as MPS II, systemic sclerosis, pulmonary arterial hypertension, and ME/CFS/Long Covid. Early-stage innovations like organ‑on‑a‑chip xenotransplantation models sit alongside non‑pharmacologic strategies such as exercise, underscoring how policy, advanced platforms, and holistic management are converging to expand options for patients long overlooked by traditional drug development.